⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8418673 | 0.93 | DDB1 (0.46) | — | |
| SCHEMBL8418672 | 0.93 | DDB1 (0.46) | — | |
| SCHEMBL13744502 | 0.92 | DDB1 (0.42) | — | |
| SCHEMBL2018032 | 0.91 | DDB1 (0.45) | — | |
| SCHEMBL2305763 | 0.86 | PIK3CD (0.48) | — | |
| SCHEMBL3436142 | 0.86 | DDB1 (0.45) | — | |
| SCHEMBL12562619 | 0.84 | KDM4E (0.44) | — | |
| SCHEMBL3435014 | 0.80 | DDB1 (0.41) | — | |
| SCHEMBL3436141 | 0.78 | DDB1 (0.43) | — | |
| SCHEMBL1513993 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111163765-B | Method for inhibiting conversion of choline to Trimethylamine (TMA) | 宝洁公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-3522878-B1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10675256-B2 | Methods for inhibiting conversion of choline to trimethylamine (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| US-10675256-B2 | Methods for inhibiting conversion of choline to trimethylamine (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| CN-111163765-A | Methods for inhibiting the conversion of choline to Trimethylamine (TMA) | 宝洁公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-3522878-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2019-08-14 | — | — | EP | disclosed |
| WO-2019070677-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190099389-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2019-04-04 | — | — | US | disclosed |
| US-20190099389-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2019-04-04 | — | — | US | disclosed |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2349260-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | Incyte Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| EP-2190838-A1 | CANNABINOID RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2010-06-02 | — | — | EP | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2009024819-A1 | CANNABINOID RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| EP-0714885-B1 | Preparation process of aminoacetamide derivative | EISAI CO LTD (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0714885-A2 | Preparation process of aminoacetamide derivative | EISAI CHEMICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |